Latest news with #InitialPublicOfferings
Time of India
3 days ago
- Business
- Time of India
Cyber police arrest two for facilitating online share trading fraud targeting senior citizen
Mumbai: Two persons, including a woman, were arrested by the cyber police for allegedly allowing their bank accounts to be used by fraudsters under the guise of a digital marketing firm. They knowingly received fraudulent funds for monetary considerations. The duo was arrested after the fraudsters impersonated share brokers and, under the pretext of lucrative returns on stocks and IPO trading, duped a senior citizen to the tune of Rs 55 lakh. The arrested accused have been identified as Santosh Kumar Tanti (30), originally from Dhanbad in Jharkhand, and Sapna Baghela Pandey (25), from Siwan in Bihar. Both were staying together in rented premises at Versova, Andheri. Police stated that their names emerged during the investigation of the complaint of a senior citizen whom the accused cheated of Rs 55 lakh. The fraudsters contacted the complainant between Jan 21 and Fe 20, 2025, via WhatsApp, impersonating representatives of a well-known brokerage firm. The scammers lured Sheth into joining a WhatsApp group and investing in Initial Public Offerings (IPOs) and stock trading through a fake trading portal. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Dermatologista recomenda: simples truque elimina o fungo facilmente Acabe com os Fungo Undo Using the pretext of lucrative returns on stock and IPO trading, the accused manipulated the victim to invest through a fake trading link, which was identical to QRL. Initially, the victim was asked to deposit small amounts. He first transferred Rs 2,00,000 to an ICICI Bank account. Later, seeing what appeared to be rising virtual profits in his so-called trading account, he continued to invest larger sums, believing he was allotted an IPO worth over Rs 10 lakh. Gaining his trust by showing inflated virtual profits, the fraudsters induced him to transfer Rs 55.41 lakh into multiple bank accounts. During the investigation, it was revealed that Rs 13 lakh of the defrauded amount was deposited into the bank account jointly operated by the two accused. Upon tracing the bank account to their Versova residence, the duo was taken into custody. During interrogation, they admitted to operating the account under the guise of a digital marketing firm and knowingly receiving fraudulent funds. A mobile phone was seized from them during the arrest, and a formal notice of arrest under Section 47 of the Indian Civil Protection Code was issued. Information about the arrest was also duly notified to the accused's contact, Jagdish Pratap Sanichar Prasad Singh, under Section 48. The accused further confessed that they facilitated the transfer of funds to other accounts with the help of one Ajay Rath, suspected to be based in Delhi. His full identity is yet to be ascertained, and efforts are ongoing to track him and others involved, said an official. The case underscores the growing menace of online impersonation fraud and highlights the importance of verifying investment platforms before transacting. Authorities urge citizens to remain vigilant and report suspicious financial schemes to the nearest cyber cell.
Yahoo
12-05-2025
- Business
- Yahoo
Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions
The CAR-T industry is booming, with a significant surge in funding driven by successful therapies hitting the market. Over 170 companies are actively developing CAR-T products, with 1,944 therapies in stages of development and 110 collaborations valued up to approximately $67.9 billion. Since 2014, 89 companies secured $7.7 billion in venture capital, while 42 IPOs raised $6.4 billion. Despite a slowdown in M&A deals in 2024, over $141.2 billion has been raised through various transactions, potentially totaling $281.7 billion with undisclosed deals. The global landscape features 13 approved CAR-T therapies primarily targeting blood cancers, with ongoing clinical trials aiming to treat solid tumors as well. Dublin, May 12, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2025" report has been added to offering. In recent years, the CAR-T industry has experienced a remarkable surge in funding. At first, the trend was subtle, but the tide has swelled as CAR-T therapies have reached the marketplace and created a funding boom. Today, CAR-T start-ups are being richly funded by investors and large pharma who are eager to get into this trending area of regenerative medicine. Worldwide, more than 170 companies are now developing CAR-T products and therapies, with a total of 1,944 early and late-stage therapies in development. These companies have also entered into 110 collaboration agreements aimed at advancing various CAR-T candidates. Of these, only 38 have disclosed the value of their deals, which amounts to $23.58 billion. If we estimate the value of the undisclosed deals, the total value of these 110 collaborations is likely to reach approximately $67.9 billion. The clinical successes of CAR-T therapies have sparked significant interest from venture capitalists globally. This increased activity has fueled advancements in CAR-T technology and the development of applications for both hematological cancers and other types of cancer. Since 2014, a total of 89 CAR-T companies have secured $7.7 billion in venture capital, enabling them to strengthen their foundations. Venture capital funding has remained strong and consistent throughout the development of the CAR-T industry. Data shows that Initial Public Offerings (IPOs) within the CAR-T space were relatively slow last year. In 2024, only Kyverna Therapeutics went public, raising $319 million to support its anti-CD19 CAR-T therapies. However, from 2014 to present, 42 CAR-T companies have gone public, collectively raising $6.4 billion to further enhance their technology platforms, clinical trials, and corporate strategies. Within this rapidly evolving industry, there are currently 72,418 patent records and 452 granted patents. As a result, large pharmaceutical companies are increasingly seeking to enter the CAR-T market by licensing patents from existing patent holders. Over the past decade, 91 CAR-T licensing deals have been valued at $6.3 billion, and this figure is expected to grow significantly over the next ten years. While 2023 saw a resurgence in dealmaking, the CAR-T industry experienced a slowdown in mergers and acquisitions (M&A) in 2024, with only two deals completed. Although major M&A activity may not return in 2025, further deals are likely as large pharmaceutical companies look to deploy their cash reserves. Over the past decade, M&A deals have accounted for the largest share of CAR-T industry financing, totaling an impressive $97.4 billion. In total, the CAR-T industry has raised more than $141.2 billion through various deal types, including IPOs, licensing deals, collaborations, and M&A transactions. It's important to note that the values of 61 out of 91 licensing deals, 75 out of 110 collaboration deals, and 12 out of 29 M&A deals remain undisclosed. If we estimate the value of these undisclosed transactions, the overall total is likely to reach a staggering $281.7 billion. Globally Approved CAR-T Therapies Since 2017, 13 CAR-T cell therapies have reached commercialization across multiple healthcare markets. Seven therapies have been approved by the U.S. FDA, after which approvals for them were issued in other major healthcare markets as well. Beyond the U.S., four CAR-T therapies-Relma-cel, Fucaso, Yuanruida, and Zever-cel - have been approved by China's National Medical Products Administration (NMPA). Additionally, two therapies, NexCAR19 and Qartemi, have received approval from India's Central Drugs Standard Control Organisation (CDSCO). All 13 approved CAR-T cell therapies are currently used exclusively to treat blood cancers, which account for less than 5% of cancer patients worldwide. Today, there are approximately 1,944 ongoing clinical trials focused on addressing both blood cancers and solid tumors. Of these, only 244 trials are targeting solid cancers. This swell of clinical trials has been driven by the remarkable 90% remission rate achieved by most of the approved CAR-T therapies. CAR-T Market Overview To track funding within this rapidly growing industry, the publisher has released this 220-page CAR-T market funding report. It summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events. This report reveals the following information for the CAR-T Cell Therapy Industry: Financing Rounds IPOs Asset Agreements Strategic Partnerships Co-Development Agreements M&A Transactions Companies Profiles for CAR-T Market Competitors You can use it to: Quantify CAR-T industry investments Identify well-capitalized companies Scout potential partnerships and alliances Understand partnerships and co-development programs for CAR-T technologies Identify M&A activity within the CAR-T industry To summarize, CAR-T companies - from emerging start-ups to billion-dollar enterprises - have completed hundreds of billions of dollars in financial transactions in recent years. These companies are rapidly expanding across global healthcare markets. This report delivers essential insights into the financial forces driving the industry, revealing where capital is flowing and how you can strategically position yourself to benefit from these trends. Key Topics Covered: 1. EXECUTIVE SUMMARY Globally-Approved CAR-T Cell Therapies 2. UPTAKE OF CAR-T THERAPIES, FULL YEAR 2017 to 2024 Number of Patients Treated with CAR-T Cell Therapies, Full Year 2017 to 2024 Sales Revenues Generated by FDA-Approved CAR-T Therapies, Full Year 2017-2024 . List Prices of U.S. FDA-Approved CAR-T Therapies 3. CAR-T FUNDING: AN OVERVIEW Venture Capital Raised by CAR-T Companies Bellicum Pharmaceuticals CRISPR Therapeutics Autolus Cellular Biomedicine Group Adicet Bio Autolus Limited Cellular Biomedicine Group Carina Biotech PeproMene Bio Precision BioSciences Cabaletta Bio Vor Biopharma Gracel Biotechnologies Mustang Bio Poseida Therapeutics BioNTech Adicet Bio Kyverna Therapeutics EXUMA Biotech IASO Biotherapeutics Legend Biotech JW Therapeutics Vor Pharma ImmPACT Bio Synthekine Gracell Biotechnologies CARsgen Therapeutics Umoja Biopharema Juventas Cell Therapy Celyad Oncology Artiva Biotherapeutics Caribou Biosciences Biosceptre Noile-Immune Biotech Arcellx Cellares Corporation Interius BioTherapeutics Synthekine Umoja Biopharma Wugen Mnemo Therapeutics AvenCell Currus Biologics Juventas Cell Therapy Carina Biotech IASO Biotherapeutics Cellular Biomedicines AffyImmune Therapeutics Leucid Bio Clade Therapeutics SOTIO Biotech EXUMA Biotech ImmPACT Bio Kyverna Therapeutics Ucello Therapeutics Mustang Bio Wugen Inceptor Bio Tessa Therapeutics Immuneel Therapeutics OriCell Therapeutics Carina Biotech Juventas Cell Therapy Arsenal Biosciences Synthekine IASO Biotherapeutics MPC Therapeutics OriCell Therapeutics Verismo Therapeutics Cargo Therapeutics OneChain Immunotherapeutics Caribou Biosciences Verismo Therapeutics Kyverna Therapeutics Gracell Biotechnologies Cellares Celyad Oncology Capstan Therapeutics Limula Cargo Therapeutics Leman Biotech Immuneel Therapeutics Dynamic Cell Therapies Arsenal Biosciences AvenCell Therapeutics March Biosciences A2 Biotherapeutics Umoja Biopharma 4. IPO FUNDING INVESTED IN CAR-T COMPANIES (42 IPOs) Descriptions of IPO Funds Raised by CAR-T Companies, Jan. 2014 to Feb. 2025 Juno Therapeutics Cellular Biomedicine Group Xenetic Biosciences Cellular Biomedicine Group Autolus Therapeutics Allogene Therapeutics Precision BioSciences Atara Biotherapeutics Xenetic Biosciences Cabaletta Bio Atara Biotherapeutics Legend Biotech Mustang Bio JW Therapeutics Atara Biotherapeutics Gracell Biotechnologies Vor Biopharma Adicet Bio CARsgen Therapeutics Xenetic Biosciences Caribou Biosciences Celyad Oncology Adicet Bio Legend Biotech Kyverna Therapeutics Arcellx TC Biopharm Celularity TC BioPharm Precision Biosciences Legend Biotech TC Biopharm Vor Biopharma Precigen TC Biopharm Celularity Legend Biotech Coeptis Therapeutics Caribou Biosciences Cargo Therapeutics Kyverna Therapeutics Mustang Bio 5. CAR-T LICENSING DEALS (90 Total) CAR-T Licensing Deals & Values, January 2015 to February 2025 Cellectis & Ohio State University bluebird bio & Five Prime Therapeutics Poseida Therapeutics & Janssen Biotech bluebird bio & ViroMed Bellicum Pharmaceuticals & Astellas Pharma CRISPR Therapeutics & MaxCyte bluebird bio & Novartis Novartis & Celyad TC Biopharm & University College London (UCL) Mustang Bio & Fred Hutchinson Cancer Research Center Mustang Bio & Harvard University bluebird bio & TC Biopharm Janssen Biotech & Legend Biotech Autolus & UCL Business Otsuka Pharmaceutical & Osaka University Cellular Biomedicine & Novartis CRISPR Therapeutics & MaxCyte Wugen & Washington University Atara Biotherapeutics & Memorial Sloan Kettering Cancer Center bluebird bio & Inhibrx Autolus Therapeutics & Noile-Immune Biotech Vor Biopharma & MaxCyte Juno Therapeutics & Oxford Biomedica Allogene Therapeutics & MaxCyte Kite & Teneobio Legend Biotech & Noile-Immune Biotech Caribou Biosciences & MaxCyte Prescient Therapeutics & University of Pennsylvania Minerva Biotechnologies & Memorial Sloan Kettering Cancer Center Luminary Therapeutics & Case Western Reserve University Beam Therapeutics & Oxford Biomedica SOTIO Biotech & Unum Therapeutics Vor Biopharma & Metagenomi Chimeric Therapeutics & City of Hope Vor Biopharma & Arbor Biotechnologies Immuneel Therapeutics & Hospital Clinic de Barcelona (HCB) Vor Biopharma & National Cancer Institute (NCI) Caribou Biosciences & Memorial Sloan Kettering Cancer Center Carina Biotech & Bionomics Atara Biotherapeutics & Bayer Cellectis & SIRION Biotech Eli Lilly & Precision BioSciences AbbVie & Caribou Biosciences Luminary Therapeutics & Bio-Techne Corporation Wugen & HCW Biologics Alpha Biopharma & Wugen Servier & Precision Biosciences Dr. Reddy's Laboratories & Pregene Biopharma Celularity & MaxCyte BioNTech & Takara Bio Bellicum Pharmaceuticals & UNC Lineberger Mustang Bio & Mayo Clinic Precision Biosciences & Tiziana Sciences Arcellx & Oxford Biomedica Carina Biotech & BayPAT Inceptor Bio & University of California Rebirthel & Otsuka Pharmaceutical Kyverna Therapeutics & National Institutes of Health (NIH) Intellia Therapeutics & Kyverna Therapeutics Antion Biosciences & Allogene Therapeutics Sana Biotechnology & IASO Biotherapeutics CellPoint & Pregene Xenetic Biosciences GO Therapeutics LG Chem & MaxCyte Roche & Poseida Therapeutics Chugai Pharmaceutical & Noile-Immune Biotech Beam Therapeutics & Orbital Therapeutics Undisclosed Company & Oxford Biomedica Coeptis Therapeutics & University of Pittsburgh Cabaletta Bio & IASO Biotherapeutics Inceptor Bio & Avectas Kite Pharma & Refuge Biotechnologies Kite Pharma & Arcellx Cabaletta Bio & Autolus Therapeutics Precigen & Alaunos Leucid Bio & ImaginAb Affini-T Therapeutics & MSK Shunxi Holding & Cartherics Janssen Biotech & Cellular Biomedicine Astellas Pharma & Poseida Therapeutics Imugene & Precision Biosciences Cabaleta Bio & Oxford Biomedica Kyverna Therapeutics & Oxford Biomedica Coeptis Therapeutics & Univerdity of Pittsburgh Janssen Biotech & Cellular Biomedicine Group Legend Biotech & Novartis Pharma AbbVie & Umoja Biopharma Astellas Pharma & Kelonia Therapeutics Allogene Therapeutics & Arbor Biotechnologies 6. CAR-T COLLABORATION DEALS (110 Total) CAR-T Collaboration Deals between January 2013 and February 2025 bluebird Bio & Celgene Corporation Pfizer, Inc. & Cellectis Amgen & Kite Pharma Five Prime Therapeutics & bluebird bio Celgene & Juno Therapeutics Cellectis & Servier Kite Pharma & Cell Design Labs Kite Pharma & Fosun Pharma Cellular Biomedicine Group & GE Healthcare Life Sciences, China Novartis & bluebird bio & Celyad Mustang Bio & Harvard University & Beth Israel Deaconess Center Jenssen Biotech & Legend Biotech PersonGen & Anke Cellular Therapeutics & Miltenyi Biotec Kite Pharma & Sangamo Therapeutics bluebird bio & Celgene Corporation AbbVie & Calibr Novartis & Fraunhofer IZI Cellular Biomedicine & Novartis Regeneron Pharmaceuticals & bluebird bio Cartherics & ToolGen TC Biopharm & Dublin's Trinity College MaxCyte & Kite Pharma Phanes Therapeutics & Phanes Biopharmaceuticals & Fosun Kite Cellectis SA & Servier Monde MaxCyte & Allogene Therapeutics Fate Therapeutics & Janssen Biotech bluebird bio & Bristol Myers Squibb Xenetic Biosciences & PJSC Pharmsynthez Fate Therapeutics & Baylor College of Medicine Beam Therapeutics & Oxford Biomedica Carina Biotech & Glytherix Chimeric Therapeutics & City of Hope Biosceptre & Carina Biotech Allogene Tx & University of Texas MD Anderson Cancer Center Oxford Biomedica & PhoreMost Limited Carina Biotech & Bionomics Bayer AG & Atara Biotherapeutics Oncternal Therapeutics & Karolinska Instituet EXUMA Biotech & Moffitt Cancer Center AbbVie & Caribou Biosciences Cytovia Therapeutics & Cellectis SAS JW Therapeutics & Thermo Fisher Scientific AbbVie & Caribou Biosciences Wugen & Alpha Biopharma Dr. Reddy's Laboratories & Shenzhen Pregene Biopharma Vor Biopharma & Abound Bio Kite Pharma & Fosun Pharmaceutical Takara Bio & BioNTech Vor Biopharma & Janssen Biotech Imugene & Celularity Gracell Biotechnologies & FutureGen Biopharm AdAlta & Carina Biotech Celularity & Oncternal Therapeutics Autolus Therapeutics & Blackstone Life Sciences 4basebio & Leucid Bio Leucid Bio & Lonza Oxford Biomedica & Arcellx Carina Biotech & Bayerische Patentallianz (BayPAT) Intellia Therapeutics & Kyverna Therapeutics Arsenal Biosciences & Bristol Myers Squibb Allogene Therapeutics & Antion Biosciences Transgene & PersonGen BioTherapeutics Immatics & Bristol Myers Squibb Legend Biotech & Janssen Biotech Umoja Biopharma & Lupagen Immatics & Celgene Immatics & Bristol Myers Squibb Umoja Biopharma & TreeFrog Therapeutics Invectys & University of Texas Cancer Center Poseida Therapeutics & Roche Chugai Pharmaceutical & Noile-Immune Biotech Kite Pharma & Arcellx Arsenal Biosciences & Genentech Autolus Therapeutics & Bristol Myers Squibb Inceptor Bio & Avectos JW Therapeutics & 2seventy bio Peter MacCallum Cancer Centre and Cartherics Umoja Biopharma & IASO Biotherapeutics Kite Pharma & Arcellx Ori Biotech & Inceptor Bio Simnova & Orna Therapeutics CARsgen Therapeutics & Huadong Medicine TC Biopharm & University of Texas MD Anderson Cancer Center Kite Pharma & Arcellx Peter MacCallum Cancer Centre & Cartherics Cartherics & Shunxi Holding Group Autolus Therapeutics & Cardinal Health Cartherics & Shunxi Janssen Biotech & Cellular Biomedicine CytoMed & University of Texas MD Anderson Cancer Center Noile-Immune Biotech & Sysmex GenScript Biotech & T-MAXIMUM Biotech CytoMed Therapeutics & Hangzhou CNK Therapeutics CARsgen Therapeutics & Moderna Cellares & Bristol Myers Squibb Celularity & Regeneron Pharmaceuticals Verily & Kyverna Therapeutics Kyverna Therapeutics & Elevate Bio Kite & Arcellx Galapagos & Thermo Fisher Scientific Calibr-Skaggs & AbbVie BioNTech & Autolus Astellas Pharma & Kelonia Therapeutics Fiocruz & Caring Cross Cartherics & TiCARos Bristol Myers Squibb Chimeric Therapeutics & Cell Therapies Nona Biosciences & Umoja Biopharma Poseida Therapeutics & Roche Takeda & Alloy Therapeutics 7. CAR-T MERGER & ACQUISITION (M&A) DEALS (29 TOTAL) Descriptions M&A Deals in CAR-T Space, January 2015 to February 205 Cellular Biomedicine & Chinese PLA General Hospital Gilead Sciences & Kite Pharma Gilead Sciences & Cell Design Labs Novartis & Endocyte Bristol Myers Squibb & Celgene Xenetic Biosciences & Scripps Research Institute Astellas Pharma & Xyphos Biosciences BioNTech & Neon Therapeutics resTORbio & Adicet Bio Century Therapeutics & Empirica Therapeutics Celularity & GX Acquisition Cellular Biomedicine & CBMG Merger Sub Amgen & Five Prime Therapeutics BioNTech & Kite ImmPACT Bio & Kalthera Kiromic Biopharma & InSilico Solutions Allogene Therapeutics & Antion Biosciences FUJIFILM Corporation & Atara Biotherapeutics Galapagos & CellPoint/AboundBio Atossa Therapeutics & Dynamic Cell Therapies Kite & Tmunity Therapeutics Janssen & Cellular Biomedicine Mustang Bio & uBriGene Biosciences Precision Biosciences & Imugene Oxford Biomedica & Institut Merieux Clade Therapeutics & Gadeta Kyowa Kirin & Orchard Therapeutics AstraZeneca & Gracell Biotechnologies Ginkgo Bioworks & Modulus Therapeutics 8. PROFILES OF COMPANIES INCLUDED IN THIS REPORT AdAlta Ltd. Adicet Bio AffyImmune Therapeutics, Inc Allogene Therapeutics Alpha Biopharma Antion Biosciences Arcellx, Inc. Arsenal Biosciences, Inc Astellas Pharma, Inc. Atara Biotherapeutics Autolus Therapeutics PLC AvenCell Therapeutics, Inc Beam Therapeutics Bellicum Pharmaceuticals, Inc Biosceptre BioNTech SE bluebird bio Cargo Therapeutics Caribou Biosciences, Inc. Carina Biotech CARsgen Therapeutics Holdings Limited Cartherics Pty Ltd Cellares Cellectis Cellular Biomedicine Group Celularity, Inc Celyad Oncology Chengdu Usano Biotechnology Co., ltd. (Ucello) Chimeric Therapeutics, Ltd Clade Therapeutics Coeptis Therapeutics, Inc. CRISPR Therapeutics Currus Biologics CytoMed Therapeutics Ltd Dynamic Cell Therapies, Inc Elicera Therapeutics Galapagos NV Gracell Biotechnologies EXUMA Biotech Corp IASO Biotherapeutics ImmPACT Bio Inceptor Bio Interius BioTherapeutics Invectys, Inc Juventas Cell Therapy, Ltd. JW Therapeutics Galapagos NV Kite Pharma (Gilead) Kyverna Therapeutics Legend Biotech Leucid Bio, Ltd Luminary Therapeutics Lupagen, Inc MaxCyte, Inc Minerva Biotechnologies Mustang Bio, Inc Noile-Immune Biotech Novartis AG OneChain Immunotherapeutics Oncternal Therapeutics, Inc OriCell Therapeutics Oxford Biomedica PLC Pepromene Bio, Inc PersonGen Bio Therapeutics (Suzhou) Co., Ltd Poseida Therapeutics, Inc. Precigen, Inc Precision BioSciences Prescient Therapeutics Simnova Biotherapeutics SOTIO Biotech B.V. TC BioPharm Umoja Biopharma Verismo Therapeutics, Inc. Vor Biopharma Wugen, Inc. Xenetic Biosciences, Inc. Xyphos Biosciences, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
The Hindu
06-05-2025
- Business
- The Hindu
IPO market loses steam on global market jitters
At least two initial Public Offerings (IPO) worth $759 million are expected to be delayed, adding to a growing list of Indian companies deciding to postpone plans for Initial Public Offerings due to weak investment sentiment, investment bankers say. Education loan provider Avanse Financial Services and contract drug maker Anthem Biosciences are among companies that will join notable names such as South Korean Conglomerate LG Electronics' India unit, to put IPO plans on hold for now, the bankers said. "There are only select institutional investors coming in at this point, given the global uncertainty," Suraj Krishnaswamy, the managing director of investment banking at Axis Capital, said. "And India-Pakistan tensions have not helped". The trend is an indication that global trade frictions and geopolitical tensions have clouded the economic outlook and caused companies to delay their capital raising and investment plans. On Tuesday (May 6, 2025), the market debut of Indian electric scooter maker Ather Energy will be a gauge of investor appetite. In pre-market activity, its shares have fluctuated around its issue price of ₹321 ($3.81), indicating a muted start. Avanse Financial and Anthem Biosciences did not respond to Reuters queries seeking comment. As many as 58 companies with Indian regulatory clearance have not launched their IPOs due to global market disruptions caused by U.S. President Donald Trump's tariffs, which have negatively affected business sentiment and fuelled recession fears. The regulatory clearances of some of these firms will expire over the next few months, PRIME Database Group MD Pranav Haldea said, forcing them to either restart the entire IPO process or seek an extension from India's market regulator. India, which was the world's second-largest IPO market last year, has seen a 58% slump in IPOs listed on the main stock exchanges so far this year, according to PRIME Database. The total fundraising on all the listing platforms has seen an 18% drop, LSEG data showed. "Things are moving slowly, but it is not a complete standstill. In the current scenario, most of the IPOs are in a similar situation," said an investment banker, who requested anonymity as he was not authorised to speak to the media. Company executives agreed "You don't want to file when you do not know how long the volatility will last," online automobile marketplace Droom's CEO Sandeep Aggarwal said, adding that his firm had decided against filing draft IPO papers by June as it had originally planned. Worried investors Retail investors, having suffered significant losses due to market volatility, are being more cautious with new investments, resulting in a lukewarm reception for this year's IPOs. Ather Energy, which decided to proceed with its $352 million IPO despite the uncertainty, had to cut its target valuation by 44% and lower its offer size though its IPO was fully subscribed. "Ather can be a risky bet given the current geopolitical issues and high valuation," Hem Securities senior research analyst Astha Jain said. The unpredictable environment is prompting bankers to urge their prospective IPO clients to adjust their strategies. "If the issue is important, then you may have to reconsider valuations. If valuation is important, then you have to wait for some more time," said Bhavesh Shah, the managing director and head of investment banking at Equirus.
Business Wire
02-05-2025
- Business
- Business Wire
The Journey to the Public Markets
Navigating the complex path to becoming a publicly traded company is a monumental decision that requires strategic planning and a thorough understanding of the capital markets. Today, there are more avenues than ever for companies to access these markets. From traditional Initial Public Offerings (IPOs) to direct listings and Special Purpose Acquisition Companies (SPACs), organizations considering going public must evaluate each option carefully to determine the best path forward for their unique circumstances. After selecting the appropriate IPO format and filing the necessary regulatory documents, the company must embark on a timely and effective external communications journey designed to educate and engage potential shareholders. Our experts dive into the critical decisions companies face when going public. We explore the nuances of each method by which a company can become publicly traded and outline the essential steps needed to communicate these choices effectively before, during, and after the initial public offering. What's covered in the webinar? A Discussion of the Current IPO Market Trends Gain insights into the latest developments shaping the IPO landscape. Understand how market volatility, investor sentiment, and regulatory changes impact the success of public offerings. Our experts analyze recent IPO activities, highlight emerging sectors attracting investor attention, and discuss what these trends mean for companies planning to go public. Options for Going Public – From Direct Listings to IPOs to SPACs We provide an in-depth comparison of the various routes to the public markets. Learn about the traditional IPO process, including underwriting, pricing, and roadshows. Discover how direct listings offer an alternative by allowing companies to list without issuing new shares or raising new capital. Explore the rise of SPACs as a faster, less conventional method, and understand how companies choose the option that best aligns with their goals and stakeholder interests. Best Practices for Communicating Your IPO Based on the Selected Format Effective communication is crucial throughout the IPO process. We discuss strategies for crafting compelling narratives that resonate with investors, regulators, and the public. Topics include tailoring your messaging to different audiences, leveraging digital media platforms, and ensuring compliance with legal and regulatory requirements. Learn how to manage investor expectations and build confidence in your company's vision and financial health. Metrics to Gauge a Successful Public Listing Understand the key performance indicators that define a successful transition to the public markets. We cover metrics such as initial stock performance, capital raised versus projected needs, market capitalization, and post-IPO growth trajectories. Our experts share insights on how to set realistic benchmarks, monitor performance, and implement strategies for sustained success in the public eye. Why You Should Watch: Expert Guidance: Learn from seasoned professionals with firsthand experience in taking companies public across various industries. Strategic Insights: Gain a comprehensive understanding of the pros and cons of each IPO route to make informed decisions. Communication Strategies: Acquire actionable tips for effectively communicating your company's story to attract and retain investors. Market Awareness: Stay updated on current trends and future projections in the IPO market to better position your company. Get Access to the Webinar: Unlock valuable knowledge that can propel your company toward a successful public offering. By watching this webinar, you'll be better prepared to make strategic decisions, communicate effectively with stakeholders, and achieve a successful public listing. Meet the Panelists Matt Rubel Executive Board Chairman, MidOcean Partners Matt Rubel currently serves as a Chairman, MidOcean Private Equity Executive Board. Matt is a renowned retail and brand CEO, having led many successful global brands and businesses. Notable past experiences include his role as CEO, President, and Board Member of Varsity Brands, Chairman, CEO and President of Collective Brands, Inc., Chairman, CEO and President of Cole Haan LLC, and senior leadership roles at J. Crew Group, Revlon, and Murjani International Ltd.
Time of India
24-04-2025
- Business
- Time of India
Rs 1.6 Cr swindled in separate investment frauds involving fake IPO platforms
New Delhi: In separate incidents, a doctor and his wife, as well as another woman, were duped out of Rs 1.6 crore by fraudsters who promised high returns on investments. In the first case, a woman from Lajpat Nagar invested Rs 83 lakh on a fake platform that claimed to offer substantial returns on investments in Initial Public Offerings (IPOs). The fraud was carried out through a platform that falsely presented itself as a legitimate international trading service. According to the complainant, the platform used sophisticated tactics, including a professional-looking interface, false promises of high returns, and staged withdrawal options, to gain her trust. Initially encouraged to invest just Rs 5,000, she said she was gradually pressured into investing larger sums through psychological manipulation and fabricated assurances of legitimacy. You Can Also Check: Delhi AQI | Weather in Delhi | Bank Holidays in Delhi | Public Holidays in Delhi The complainant informed the police that the fraudulent platform claimed to offer high-yield investments in UC stocks, indexes, and IPOs. "It initially allowed small withdrawals to build investor confidence. However, once significant funds were deposited, the platform imposed withdrawal restrictions and stopped providing meaningful customer support," the complainant stated. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Bavdhan: 3BHK Interiors starting at 4.5 Lakhs HomeLane Get Quote Undo On Feb 17, the platform rebranded itself, changing its name, which the complainant believes was a tactic to disguise its fraudulent nature. Despite the rebranding, the platform remains operational and continues to lure new victims. In another case, a doctor and his wife were similarly duped after investing Rs 77 lakh in a fraudulent website. The couple told the police that the fraud began when they were tricked into joining a dubious mobile app that promised IPO allocations. After downloading the app, they were led to believe they had secured allocations in multiple IPOs, only to be instructed to transfer large sums of money into various bank accounts across the country, with no direct connection to any legitimate trading platforms. The fraudulent transactions, which took place over several dates in Jan and Feb 2025, involved a total of 14 transactions. The couple grew suspicious after repeated requests to deposit significant sums into unrelated accounts, prompting them to file a complaint.
